论文部分内容阅读
Sizofiran(SPG)与放疗并用可延长晚期宫颈癌患者的生命,但其免疫机制还不清楚。现对癌进展第一道防线局部淋巴结淋巴细胞(PLNL)的免疫功能,尤其对IL-2/IL-2R系统的效果报告如下。 44例宫颈癌手术患者,术前日肌注SPG20mg/次(0期9例、Ⅰb期5例)。或术前第8日和手术前日各肌注20mg/次(0期10例、Ⅰb期5例),与未投药组(0期10例、Ⅰb期5例)进行比较。手术时无菌采骨盆(髂内)淋巴结淋巴细胞,经Ficoll-Hypaque比重离心法分离,进行机能测定。IL-2产生能:分离的淋巴细胞用PHAP(0.5
Sizofiran (SPG) combined with radiotherapy can prolong the life of patients with advanced cervical cancer, but its immune mechanism is unclear. The immune function of the first line of defense local lymph node lymphocytes (PLNLs), especially the effect on the IL-2 / IL-2R system, is reported below. 44 cases of cervical cancer surgery patients, preoperative day muscle injection SPG20mg / times (0 in 9 cases, Ⅰ b in 5 cases). Or 20mg / time intramuscular injection (10 cases in stage 0, 5 cases in stage Ib) before operation on the 8th day and the day before operation, and no treatment group (10 cases in stage 0, 5 cases in stage Ib). During surgery, pelvic (iliac) lymph node lymphocytes were aseptically collected and centrifuged by Ficoll-Hypaque gravity centrifugation to determine their function. IL-2 Production Ability: Isolated lymphocytes were treated with PHAP (0.5